France Boosts Doliprane Production Amid Major Domestic Investment Surge

At the opening of the Choose France summit on November 17, French Economy Minister Roland Lescure announced Opella's plans to increase Doliprane production by over 30%, raising output from 450 million to 600 million boxes annually. This expansion targets the manufacturing sites in Lisieux and Compiègne, following Sanofi's partial sale of Doliprane to an American investment fund — though Sanofi retains a 48.2% stake, and Bpifrance holds 1.8% to protect French strategic interests.

The summit highlighted robust investment activity with a total of €30.4 billion committed across 151 projects nationwide. Of this, €21.2 billion had already been declared previously, and €9.2 billion represented new investments spread across multiple sectors such as energy, green industries, and health. Other notable investments include Thesee's venture into data centers and Urgo's announcement of a new factory in the Loire region backed by a €60 million investment slated for completion by 2029.

These developments mark a significant commitment to reshoring and expanding pharmaceutical manufacturing in France, aiming to secure supply chains and strengthen domestic capacity amidst global competitiveness.